NOX66
Sponsors
Noxopharm Limited
Conditions
CancerCovid19Metastatic Castration-resistant Prostate Cancer and Other Solid TumorsMetastatic Soft-tissue Sarcoma
Phase 1
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
CompletedNCT02941523
Start: 2017-03-03End: 2019-01-10Updated: 2021-06-02
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
CompletedNCT03307629
Start: 2017-11-01End: 2020-09-15Updated: 2025-07-29
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19
CompletedNCT04555213
Start: 2020-09-30End: 2021-08-10Updated: 2021-08-26
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
TerminatedNCT04957290
Start: 2021-10-25End: 2023-06-07Updated: 2024-06-18
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
TerminatedNCT05100628
Start: 2022-02-11End: 2023-05-26Updated: 2025-01-06